DE-CSC
8.10.2020 12:02:07 CEST | Business Wire | Press release
CSC , a world leader in business, legal, tax, and domain security, today released new research from their Digital Brand Services (DBS) division that reveals areas of risk for prominent election-related websites. The research indicates that web domains closely linked to the campaign websites for Joe Biden and Donald Trump lack basic domain security protocols and are being targeted for disinformation activities such as domain spoofing, and threats including domain name and domain name system (DNS) hijacking, and phishing.
On the heels of its recent Forbes Global 2000 research , CSC is seeing major risks related to the manipulation of web properties that voters rely on for information and donations. Findings show that over 90% of these web properties are not using registry locks to protect their domains from domain and DNS hijacking that can lead to phishing attacks, network breaches, and email compromise.
“As noted in our previous research, we’ve consistently seen domains emerge as a threat vector for enterprises, and an area that is continuously overlooked in cyber security. Due to the sensitivity and importance of the U.S. election process, domain security remains a major vulnerability for the potential of foreign interference, fraud, and misinformation,” says Mark Calandra, executive vice president for CSC DBS. “As an organization with the most visibility into the domain landscape, we advocate for the sanctity of voter trust and encourage both presidential candidates and other websites in the electoral ecosystem to prioritize domain security on their websites to ensure security and build confidence.”
"We have reached the point where awareness is not enough. Those responsible for managing domain registrations, including registrars and hosting companies, need to have an actionable plan that is aligned with best practices. Additionally, experiences must be shared between those within the industry for the good of the wider internet community," said Matthew Stith, industry liaison at Spamhaus. “Without this commitment, users will be open to continued manipulation and fraud."
In April of 2020 when domain names were at the center of many COVID-19 related fraud schemes, Senators Mazie K. Hirono (D-Hawaii), Cory Booker (D-N.J.), and Maggie Hassan (D-N.H.) called on domain name registrars and hosting sites to combat scams and misinformation. CSC’s research shows that domain security and preventing domain spoofing continue to be an oversight even with top election-related web properties. Our research shows that more than 75% of these election-related domains are using retail-grade domain registrars, which do not provide advanced security protocols.
Our research also showed that, of the typo domains related to joebiden.com and donaldjtrump.com , 60% are still available for registration, thereby posing future threats. Additionally, more than a third of those presidential candidate typo domains are linked to third parties; of that one third, nearly 70%:
- Are configured to send and receive emails, which can be used to lure donors to phishing sites
- Were registered in 2020 leading up to the November election
- Disguise the owner’s identity behind proxy or privacy services
With cyber criminals subverting activities on these websites to disseminate misinformation or commit fraud against web visitors, there is also the threat of ransomware. Simon Chassar, chief revenue officer at NTT Ltd.’s Security division states, "NTT's September Monthly Threat Report identified ransomware as a significant threat to the U.S. election infrastructure. With DNS, domains, and email being a potential vehicle to distribute malicious content, our NTT Ltd. Security division suggests focus in this area, ensuring it is secure by design."
For additional details on these findings, visit the CSC blog “U.S. Election-Related Web Properties Prone to Fraud and Misinformation Due to Lack of Domain Security.”
Note: CSC aggregated this data using SimilarWeb.com for the period of August 1 – August 30, 2020.
About CSC
CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system (DNS), digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known security blind spots that exist and help them secure their digital assets. By leveraging CSC’s proprietary solutions, companies can get secure to protect against cyber threats to their online assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005203/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
